CD8A and cancer: Another phase II clinical study (NCT01881867) (87), initiated by Pachynski et al., reported that subcutaneous administration of IL-7 resulted in the expansion of CD4+, CD8+, and γδ T cells in prostate cancer patients treated with sipuleucel-T, a therapeutic cancer vaccine proved by Food and Drug Administration (92).